An overdose can happen at any time
MAKE SURE
YOUR PATIENTS
ARE PREPARED
An overdose can happen at any time
MAKE SURE
YOUR PATIENTS
ARE PREPARED
An overdose can happen at any time
MAKE SURE
YOUR PATIENTS
ARE PREPARED
85%
OF OPIOID OVERDOSE DEATHS
were due to synthetic opioids from April 2020 to April 20211
≈50%
OF OPIOID OVERDOSES
are estimated to require more than 1 dose of naloxone2
430%
INCREASE IN SEIZED FENTANYL-LACED COUNTERFEIT PILLS
since 2019; 40% contained a potentially lethal dose3
85%
OF OPIOID OVERDOSE DEATHS
were due to synthetic opioids from April 2020 to April 20211
≈50%
OF OPIOID OVERDOSES
are estimated to require more than 1 dose of naloxone2
430%
INCREASE IN SEIZED FENTANYL-LACED COUNTERFEIT PILLS
since 2019; 40% contained a potentially lethal dose3
The number of seized counterfeit pills containing fentanyl during an 8-week period in 2021 was enough to potentially kill >700,000 people3
WHEN EVERY MOMENT MATTERS
it’s critical that your patients are getting a high enough dose of naloxone.4
WHY A HIGH NALOXONE DOSE?
HELPFUL TIPS FOR TALKING TO
PATIENTS ABOUT ZIMHI
In an opioid overdose emergency,
ZIMHI MAY MAKE ALL
THE DIFFERENCE
REQUEST A TRAINING DEVICE
In an opioid overdose emergency,
ZIMHI MAY
MAKE ALL THE
DIFFERENCE
REQUEST TRAINING DEVICE
In an opioid overdose emergency,
ZIMHI MAY
MAKE ALL THE
DIFFERENCE
REQUEST TRAINING DEVICE
References: 1. Provisional drug overdose death counts. Centers for Disease Control and Prevention. Updated October 13, 2021. Accessed December 9, 2021. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm 2. CT EMS SWORD: Statewide Opioid Reporting Directive Newsletter. Connecticut Dept of Health. Accessed October 20, 2021. https://portal.ct.gov/-/media/Departments-and-Agencies/DPH/dph/ems/pdf/SWORD/SWORD-newsletters/2021/SWORDSept2021NL_FINAL.pdf 3. Department of Justice Announces DEA Seizures of Historic Amounts of Deadly Fentanyl-Laced Fake Pills in Public Safety Surge to Protect U.S. Communities. Department of Justice. Published September 30, 2021. Accessed December 22, 2021. justice.gov/opa/pr/department-justice-announces-dea-seizures-historic-amounts-deadly-fentanyl-laced-fake-pills 4. FDA Advisory Committee on the most appropriate dose or doses of naloxone to reverse the effects of life-threatening opioid overdose in the community settings. Adapt Pharma Operations Limited; 2016.
INDICATION
ZIMHI is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ZIMHI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZIMHI is not a substitute for emergency medical care.
IMPORTANT SAFETY INFORMATION
As the duration of action of naloxone hydrochloride is shorter than many opioids, keep the patient under continued surveillance and administer repeated doses of naloxone using a new ZIMHI device, as necessary, while awaiting emergency medical assistance.
Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine may be incomplete. Repeat doses of ZIMHI may be required.
Use in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of signs and symptoms of opioid withdrawal.
Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular (CV) effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
After use, the ZIMHI needle is exposed until the safety guard is deployed. A needlestick injury could occur during use in emergency situations. In the event of accidental needlestick injury, medical attention should be sought.
The following adverse reactions were most commonly observed in ZIMHI clinical studies: dizziness, lightheadedness, and elevated bilirubin.
To report SUSPECTED ADVERSE REACTIONS, call 1-800-230-3935 or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch
IMPORTANT SAFETY INFORMATION and INDICATION for ZIMHI™
As the duration of action of naloxone hydrochloride is shorter than many opioids, keep the patient under continued surveillance and administer repeated doses of naloxone using a new ZIMHI device, as necessary, while awaiting emergency medical assistance.
Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine may be incomplete. Repeat doses of ZIMHI may be required.
IMPORTANT SAFETY INFORMATION and INDICATION for ZIMHI™
As the duration of action of naloxone hydrochloride is shorter than many opioids, keep the patient under continued surveillance and administer repeated doses of naloxone using a new ZIMHI device, as necessary, while awaiting emergency medical assistance.
